Survival after Trastuzumab Therapy in Patients with Locally Advanced or Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer: A Meta-Analysis of Randomized Controlled Trials

被引：0

作者：

Ali, Mohammad D. ^{[1
,5
]}

Al-Matouq, Jenan A. ^{[2
]}

Ahmad, Ayaz ^{[1
]}

Patel, Munfis ^{[2
]}

Alshnbari, Afnan S. ^{[1
]}

Alhussini, Sara H. ^{[3
]}

Almozien, Sara F. ^{[3
]}

Alowaywi, Ghadeer A. ^{[3
]}

Kannan, Latha S. ^{[4
]}

机构：

[1] Mohammed Al Mana Coll Med Sci, Dept Pharm, Dammam, Saudi Arabia

[2] Mohammed Al Mana Coll Med Sci, Dept Clin Lab Sci, Abdulrazaq Bin Hammam St, Dammam 34222, Saudi Arabia

[3] Mohammed Al Mana Coll Med Sci, Dept Resp Care, Dammam, Saudi Arabia

[4] Mohammed Al Mana Coll Med Sci, Dept Nursing, Dammam, Saudi Arabia

[5] Mohammed Al Mana Coll Med Sci, Dept Pharm, Abdulrazaq Bin Hammam St, Dammam 34222, Saudi Arabia

来源：

JOURNAL OF PHARMACY AND BIOALLIED SCIENCES | 2024年 / 16卷 / 01期

关键词：

HER2-positive gastric cancer; meta-analysis; randomized controlled trials; trastuzumab;

D O I：

10.4103/jpbs.jpbs_563_23

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Background:In the Trastuzumab for Gastric Cancer study, it was found that trastuzumab combined with doublet chemotherapy (fluoropyrimidine and platinum) was the gold-standard treatment for gastroesophageal adenocarcinoma (GEA) that was locally advanced, unresectable, or metastatic (HER2+).Materials and Methods:We performed a meta-analysis of randomized phase II/III studies testing trastuzumab in combination or alone.Results:This meta-analysis's findings involved 2048 patients in total. The treatment arm and hormone receptor status were used to stratify the combined HR. Overall, the PFS (Random model) HR [0.80] and 95% confidence intervals (CI) [0.68-0.95] were significantly higher for regimens containing trastuzumab, fluoropyrimidine, and platinum compared to regimens containing fluoropyrimidine and platinum.Conclusions:The results of this meta-analysis provide additional support for trastuzumab's use in treating HER2-positive GEA, particularly in cases where the disease lacks a HER2+ receptor.

引用

页码：24 / 30

页数：7

共 15 条

[1] Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial [J].

Bang, Yung-Jue ;

Van Cutsem, Eric ;

Feyereislova, Andrea ;

Chung, Hyun C. ;

Shen, Lin ;

Sawaki, Akira ;

Lordick, Florian ;

Ohtsu, Atsushi ;

Omuro, Yasushi ;

Satoh, Taroh ;

Aprile, Giuseppe ;

Kulikov, Evgeny ;

Hill, Julie ;

Lehle, Michaela ;

Ruschoff, Josef ;

Kang, Yoon-Koo .

LANCET, 2010, 376 (9742) :687-697

[2] HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology [J].

Bartley, Angela N. ;

Washington, Mary Kay ;

Colasacco, Carol ;

Ventura, Christina B. ;

Ismaila, Nofisat ;

Benson, Al B., III ;

Carrato, Alfredo ;

Gulley, Margaret L. ;

Jain, Dhanpat ;

Kakar, Sanjay ;

Mackay, Helen J. ;

Streutker, Catherine ;

Tang, Laura ;

Troxell, Megan ;

Ajani, Jaffer A. .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04) :446-+

[3]

European Medicines Agency, Teysuno (tegafur/gimeracil/oteracil)

[4] Tegafur/gimeracil/oteracil (S-1) approved for the treatment of advanced gastric cancer in adults when given in combination with cisplatin: a review comparing it with other fluoropyrimidine-based therapies [J].

Kobayakawa, Masao ;

Kojima, Yasushi .

ONCOTARGETS AND THERAPY, 2011, 4 :193-201

[5] Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trial [J].

Liu, Tianshu ;

Qin, Yanru ;

Li, Jin ;

Xu, Ruihua ;

Xu, Jianming ;

Yang, Shujun ;

Qin, Shukui ;

Bai, Yuxian ;

Wu, Changping ;

Mao, Yixiang ;

Wu, Haiyan ;

Ge, Yilin ;

Shen, Lin .

CANCER COMMUNICATIONS, 2019, 39

[6] Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].

Lordick, F. ;

Mariette, C. ;

Haustermans, K. ;

Obermannova, R. ;

Arnold, D. .

ANNALS OF ONCOLOGY, 2016, 27 :v50-v57

[7] Effectiveness and safety of oxaliplatin compared to cisplatin for advanced, unresectable gastric cancer: a systematic review and meta-analysis [J].

Montagnani, Francesco ;

Turrisi, Gina ;

Marinozzi, Claudio ;

Aliberti, Camillo ;

Fiorentini, Giammaria .

GASTRIC CANCER, 2011, 14 (01) :50-55

[8] Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study [J].

Sawaki, Akira ;

Ohashi, Yasuo ;

Omuro, Yasushi ;

Satoh, Taroh ;

Hamamoto, Yasuo ;

Boku, Narikazu ;

Miyata, Yoshinori ;

Takiuchi, Hiroya ;

Yamaguchi, Kensei ;

Sasaki, Yasutsuna ;

Nishina, Tomohiro ;

Satoh, Atsushi ;

Baba, Eishi ;

Tamura, Takao ;

Abe, Takashi ;

Hatake, Kiyohiko ;

Ohtsu, Atsushi .

GASTRIC CANCER, 2012, 15 (03) :313-322

[9] HELOISE: Phase IIIb Randomized Multicenter Study Comparing Standard-of-Care and Higher-Dose Trastuzumab Regimens Combined With Chemotherapy as First-Line Therapy in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma [J].

Shah, Manish A. ;

Xu, Rui-hua ;

Bang, Yung-Jue ;

Hoff, Paulo M. ;

Liu, Tianshu ;

Herraez-Baranda, Luis A. ;

Xia, Fan ;

Garg, Amit ;

Shing, Mona ;

Tabernero, Josep .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (22) :2558-+

[10] Efficacy of trastuzumab emtansine in Japanese patients with previously treated HER2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma: A subgroup analysis of the GATSBY study [J].

Shitara, Kohei ;

Honma, Yoshitaka ;

Omuro, Yasushi ;

Yamaguchi, Kensei ;

Chin, Keisho ;

Muro, Kei ;

Nakagawa, Shintaro ;

Kawakami, Satoe ;

Hironaka, Shuichi ;

Nishina, Tomohiro .

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 (01) :5-13

← 1 2 →